Skip to main content
Health Podcast Library
Season 5 • Episode 3

Identifying new therapies for Neurofibromatosis Type 1

The Promise of Discovery · 17 min

Episode Description

Neurofibromatosis Type 1 (NF1) is a neurodevelopmental disease which affects about 100,000 people in the US. Around 80% of these patients experience cognitive and intellectual impairments which are unaffected by currently approved therapies for NF1. A recent genetic study from our lab identified an association between the NF1 disease and a receptor protein called metabotropic glutamate receptor 7 (mGlu7). This project investigates how using small molecules to augment mGlu7 function could help identify new therapies for NF1 patients struggling with cognitive impairments.

Featuring: Harrison Parent, Ph.D. Candidate- Niswender Lab, Department of Pharmacology, Vanderbilt University School of Medicine

Interviewer: Colleen Niswender, Ph.D., Associate Professor of Pharmacology; Director of Molecular Pharmacology, Warren Center for Neuroscience Drug Discovery, and a Vanderbilt Kennedy Center Member

Proudly Supported by

BetterHelpForvis MazarsAAOSCalendarPAmowPod

Patrons of Health Podcast Library

OrthoInfo
AAOS Now Podcast
Achieving Health
AAOS Career Podcast
Aging Like a Pro
Stronger After Stroke
Who the Health Cares? with Prof Michael Sparer

Supporting Shows

HIT Like a Girl Pod: Empowering Women in Health IT
Speak Up For Your Health
Beyond The Paper Gown Podcast
Cuts and Consults
On the Pulse Podcast
Nurse Rosa's INsights
Impulse | Meeting Healthcare Pioneers
Beyond Clinical Walls
Coffee Break: Breaking the Cycle of Bullying in Healthcare, One Cup at a Time
Hopeful Hints
This Just In Radio Show
Faces of Digital Health
HITea With Grace
Healthcare for Humans
Coaching Healthcare Leaders
Thriving with Addiction with Dr. Jonathan Avery

We use cookies to run this site. Analytics cookies, which show us how it's used, stay off unless you accept them. Change your mind any time with the cookie button at the bottom right. How we use cookies